HomeCompareCLVLY vs SBUX

CLVLY vs SBUX: Dividend Comparison 2026

CLVLY yields 0.36% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVLY wins by $148.0K in total portfolio value· pulled ahead in Year 9
10 years
CLVLY
CLVLY
● Live price
0.36%
Share price
$7.24
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$305.5K
Annual income
$199,327.02
Full CLVLY calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — CLVLY vs SBUX

📍 CLVLY pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVLYSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVLY + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVLY pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVLY
Annual income on $10K today (after 15% tax)
$30.66/yr
After 10yr DRIP, annual income (after tax)
$169,427.97/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, CLVLY beats the other by $113,463.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVLY + SBUX for your $10,000?

CLVLY: 50%SBUX: 50%
100% SBUX50/50100% CLVLY
Portfolio after 10yr
$231.5K
Annual income
$132,583.57/yr
Blended yield
57.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

CLVLY
No analyst data
Altman Z
17.2
Piotroski
5/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVLY buys
0
SBUX buys
0
No recent congressional trades found for CLVLY or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVLYSBUX
Forward yield0.36%2.75%
Annual dividend / share$0.03$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%48.3%
Portfolio after 10y$305.5K$157.5K
Annual income after 10y$199,327.02$65,840.13
Total dividends collected$276.6K$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: CLVLY vs SBUX ($10,000, DRIP)

YearCLVLY PortfolioCLVLY Income/yrSBUX PortfolioSBUX Income/yrGap
1$10,772$72.13$11,107$407.21$335.00SBUX
2$11,671$145.24$12,512$626.87$841.00SBUX
3$12,783$294.14$14,366$978.69$1.6KSBUX
4$14,279$602.13$16,929$1,557.50$2.6KSBUX
5$16,536$1,257.27$20,658$2,543.80$4.1KSBUX
6$20,415$2,721.45$26,406$4,302.22$6.0KSBUX
7$28,124$6,280.07$35,877$7,622.00$7.8KSBUX
8$46,264$16,171.07$52,741$14,352.64$6.5KSBUX
9← crossover$99,224$49,721.74$85,676$29,243.03+$13.5KCLVLY
10$305,497$199,327.02$157,513$65,840.13+$148.0KCLVLY

CLVLY vs SBUX: Complete Analysis 2026

CLVLYStock

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Full CLVLY Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this CLVLY vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVLY vs SCHDCLVLY vs JEPICLVLY vs OCLVLY vs KOCLVLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.